Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of GSK3003891A RSV vaccine formulations in healthy women
2014-002688-14Phase 2Completed
- Sponsor
- GSK
- Start
- Nov 2014
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of respiratory syncytial virus vaccine, recombinant, adjuvanted in respiratory syncytial virus disease (RSV) (3 arms), sponsored by GSK. Primary endpoint: Occurrence of adverse events from vaccination up to Day 30. Started Nov 2014; status: completed.
02
Drugs
respiratory syncytial virus vaccine, recombinant, adjuvanted
03
Conditions
respiratory syncytial virus disease (RSV)
Beyond the preview
Go deeper on 2014-002688-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-002688-14.